Blog
RSS FeedPosted by Michael Wonder on 14 Aug 2024
Relugolix for the treatment of patients with hormone sensitive prostate cancer
14 August 2024 - NICE has published final evidence-based recommendations on the use of relugolix (Orgovyx) for the treatment of ...
Posted by Michael Wonder on 09 Aug 2024
Enzalutamide for the treatment of patients with non-metastatic prostate cancer after radical prostatectomy or radiotherapy
8 August 2024 - NICE is unable to make a recommendation about the use in the NHS of enzalutamide for the ...
Posted by Michael Wonder on 08 Aug 2024
World’s first gene editing therapy for blood disorder to be available to hundreds of patients in England
8 August 2024 - Patients in England with severe beta-thalassaemia will be amongst the first in Europe to benefit from one-time ...
Posted by Michael Wonder on 07 Aug 2024
14,000 women at risk of fractures after the menopause to benefit from bone disease drug
8 August 2024 - Over 14,000 people to benefit after NICE published final guidance recommending abaloparatide as an option for treating ...
Posted by Michael Wonder on 07 Aug 2024
Burosumab for the treatment of adults with X-linked hypophosphataemia
7 August 2024 - NICE has issued evidence-based recommendations on the use burosumab (Crysvita) for the treatment of adults X‑linked ...
Posted by Michael Wonder on 07 Aug 2024
Abaloparatide for the treatment of women with osteoporosis after menopause
6 August 2024 - NICE has issued dvidence-based recommendations on the use of abaloparatide (Eladynos) for treatment of osteoporosis after ...
Posted by Michael Wonder on 30 Jul 2024
NICE disappointed companies unwilling to offer fair price to make Enhertu available for advanced breast cancer
29 July 2024 - Daiichi Sankyo and partner company AstraZeneca have been unwilling to offer a price that would enable NICE ...
Posted by Michael Wonder on 25 Jul 2024
New clot busting drug recommended by NICE set to save NHS millions of pounds
24 July 2024 - Giving a new clot busting drug to people who have had a stroke could help save the ...
Posted by Michael Wonder on 19 Jul 2024
More than 40,000 people could benefit after NICE recommends new ‘take at home’ pill for advanced prostate cancer
19 July 2024 - A new pill to treat advanced hormone sensitive prostate cancer that could benefit just over 40,000 ...
Posted by Michael Wonder on 10 Jul 2024
NICE recommends Ebglyss (lebrikizumab) for use in moderate to severe atopic dermatitis in the NHS England in eligible adolescents and adults
10 July 2024 - Following approval of the European Commission (October 2023) and the MHRA (December 2023), lebrikizumab will be available ...
Posted by Michael Wonder on 10 Jul 2024
Lisocabtagene maraleucel for the treatment of adults with relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
10 July 2024 - NICE is unable to make a recommendation about the use in the NHS of lisocabtagene maraleucel (Breyanzi) ...
Posted by Michael Wonder on 29 Jun 2024
NICE recommends CSL Behring’s haemophilia B gene therapy Hemgenix
28 June 2024 - NICE has recommended CSL Behring’s haemophilia B gene therapy Hemgenix (etranacogene dezaparvovec) for immediate reimbursement by ...
Posted by Michael Wonder on 22 Jun 2024
NICE enables access to first treatment that targets the underlying pathophysiology of rare disease X-linked hypophosphataemia in adults
21 June 2024 - Kyowa Kirin is delighted by the decision made today by NICE to recommend Crysvita for the treatment ...
Posted by Michael Wonder on 19 Jun 2024
Tafamidis meglumine for the treatment of patients with transthyretin amyloidosis with cardiomyopathy (final guidance)
19 June 2024 - NICE has published final evidence-based recommendations on the use of tafamidis meglumine (Vyndaqel) for the treatment ...
Posted by Michael Wonder on 13 Jun 2024
Baricitinib for the treatment of patients with juvenile idiopathic arthritis
13 June 2024 - NICE is unable to make a recommendation on the use in the NHS of baricitinib (Olumiant) for ...